تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
19.55 US$
+0.24 US$ · +1.24%
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
الإغلاق السابق
19.55 US$
+0.24 US$ · +1.24%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
نطاق اليوم
السعر الحالي 19.55 US$
نطاق 52 أسبوعًا
السعر الحالي 19.55 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
بيع
تقييم
15
مبالغ في سعره
المشاعر
75
صعودي
المخاطر
55
مخاطر أعلى من المعتاد
الزخم
59
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
نطاق اليوم
السعر الحالي 19.55 US$
نطاق 52 أسبوعًا
السعر الحالي 19.55 US$
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
33.00 US$
ارتفاع محتمل بنسبة 68.80%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI88.66 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM53.61 مليون0.07%78.74 مليار USD0.19%278.94 US$+0.49%
State Street SPDR S&P Biotech ETFXBI38.19 مليون0.39%9.87 مليار USD0.35%153.77 US$+3.00%
Vanguard Extended Market ETFVXF33.93 مليون0.03%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO18.82 مليون0.14%13.92 مليار USD0.24%356.78 US$+0.94%
Vanguard Russell 2000 ETFVTWO16.61 مليون0.09%18 مليار USD0.06%112.66 US$+0.50%
Schwab U.S. Small-Cap ETFSCHA11.61 مليون0.05%21.82 مليار USD0.03%32.79 US$+0.40%
Vanguard Health Care ETFVHT8.06 مليون0.04%22 مليار USD0.09%319.01 US$+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
